Table 1: RA patients and disease characteristics.
|
Variable |
|
N = 100 |
|
Female gender (%) |
|
92 |
|
|
|
|
|
Age (years) ± SD (range) |
|
56.63 ± 9.8 (33-74) |
|
|
|
|
|
Tabaco exposure (%) |
|
7 |
|
|
|
|
|
Height(m), mean ± SD (range) |
|
9.97 ± 35.97(142-175) |
|
|
|
|
|
Weight(kg), mean ± SD (range) |
|
71.22 ± 14.61(40-109) |
|
|
|
|
|
BMI (kg/m2), mean ± SD (range) |
|
27.81 ± 5.1(17-40) |
|
|
|
|
|
FR positivity (%) |
|
64 |
|
|
|
|
|
ACPA positivity (%) |
|
60 |
|
|
|
|
|
Erosive (%) |
|
83.2 |
|
|
|
|
|
Use of Glucocorticoid (%), |
|
69.3 |
|
Glucocorticoid daily dose (mg) |
|
4.9 |
|
|
|
|
|
Use of csDMARDs (%) |
|
74.3, |
|
Methotrexate (%) |
|
16.8 |
|
|
|
|
|
Sulfasalazine (%) |
|
64.4 |
|
|
|
|
|
Methotrexate + Salazopyrine (%) |
|
8.9 |
|
|
|
|
|
Leflunomide (%) |
|
3 |
|
|
|
|
|
Use of bDMARD (%) |
|
31.7 |
|
TNF inhibitors |
|
13 |
|
IL6 inhibitors |
|
13.9 |
|
Rituximab |
|
5 |
|
|
|
|
|
CRP (mg/l), mean ± SD (range) |
|
11.87 ± 14.7 (2.1-63) |
|
|
|
|
|
DAS28, mean ± SD (range) |
|
3.70 ±1.57 (1.2-6.9) |
|
|
|
|
|
HAQ, mean ± SD (range) |
|
0.92 ± 0.81 (0.2-2.8) |
SD: Standard Deviation; RF: Rheumatoid Factor (IU/Ml); ACPA: Anti-Cyclic Citrullinated Peptide Antibody; Cs: Conventional Synthetic; DMARD: Disease Modifying Anti-Rheumatic Drugs; TNF: Tumor Necrosis Factor; IL: Interleukin; Min: Minimum; Max: Maximum; Kg: Kilogram; CRP: C Reactive Protein; DAS 28: Disease Activity Score 28; HAQ: Health Assessment Questionnaire